A study to assess whether two different doses of antenatal intravenous iron administration (500 mg and 1000mg ferric carboxymaltose) are equivalent in replenishing and sustaining iron stores successfully in pregnant iron deficient women

Trial Profile

A study to assess whether two different doses of antenatal intravenous iron administration (500 mg and 1000mg ferric carboxymaltose) are equivalent in replenishing and sustaining iron stores successfully in pregnant iron deficient women

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms PROTECTIVE
  • Most Recent Events

    • 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top